Proteomics 2003

Chapter 1: Executive Summary 8

• Introduction 9
• Applications 10
• Interviews with Experts 11
• Competitive Environment 12
• State of the Market in 2003 13
  • Successes 13
  • Challenges 14
  • Scenarios 16
• Market Size 17
  • Total 17
  • By Technology 18
  • By Applications 19

Chapter 2: Technology 20

• Introduction 21
• Output versus Throughput 22
• Mass Spectrometry 23
  • Introduction 23
  • Ionization Methods 24
  • Mass Analysis Methods 25
  • Common Instrument Configurations 27
  • A Typical Proteomic Analysis 28
  • Quantitative Methods 29
• Protein Separation 30
  • 2-D Gel Electrophoresis 30
  • Chromatography 31
• Parallelized Screening Methods 32
  • Protein Biochips 32
  • Bead-Based Methods 34
• Functional Proteomics 35
  • Overview 35
  • Map 36

Chapter 3: Applications 37

• Expression and Function 38
• Target/Biomarker Discovery 39
• Target/Biomarker Validation 40
• Drug Development 42
• Clinical Trials/ Diagnostics 45

Chapter 4: Interviews with Experts 47

• Introduction 48
• Successes 49
• Challenges 50
• The Looming Validation Bottleneck 51
• Expert 1 52
• Expert 2 56
• Expert 3 59
• Expert 4 62
• Expert 5 65
• Expert 6 66
• Expert 7 68
• Expert 8 70
• Expert 9 72
• Expert 10 74

Chapter 5: Company Evaluations 76

• Mass Spectrometry 77
  • Agilent Technologies Inc. 78
  • Applied Biosystems Group 80
  • Bruker Daltonics, Inc. 82
  • PerkinElmer Life Sciences 84
  • Shimadzu Biotech 87
  • Target Discovery, Inc. 89
  • Thermo Finnigan 91
  • Waters Corporation 93
• Protein Separation 95
  • Amersham Biosciences 96
  • Beckman Coulter, Inc. 98
  • Bio-Rad Laboratories, Inc. 100
  • Eurogentec Proteomics GmbH 101
  • Proteome Systems Ltd. 103
• Parallelized Screening Methods 105
  • Affibody AB 106
  • Archemix Corporation 107
  • Aspira Biosystems, Inc. 110
  • BD Biosciences 113
  • Biacore International AB 116
  • BioForce Nanosciences, Inc. 118
  • BioInvent International AB 121
  • Biosite Incorporated 123
  • Cambridge Antibody Technology Group plc 126
  • Ciphergen Biosystems, Inc. 128
  • CombiMatrix 131
  • Corning Incorporated Life Sciences 134
  • Discerna Ltd. 136
  • Domantis Limited 138
  • GeneScan Europe AG 139
  • HTS Biosystems, Inc. 142
  • Hypromatrix, Inc. 145
  • Jerini AG 147
  • Large Scale Biology Corporation 151
  • LumiCyte, Inc. 154
  • Luminex Corporation 156
  • Molecular Staging Inc. 158
  • nanotype GmbH 160
  • NextGen Sciences Ltd. 163
  • Pepscan Systems BV 167
  • Phylos, Inc. 170
  • Procognia Ltd. 172
  • Protagen AG 174
  • ProteinOne Inc. 177
  • Protiveris Inc. 179
  • Protometrix, Inc. 181
  • Randox Laboratories Ltd. 185
  • SomaLogic, Inc. 187
  • TeleChem International, Inc. 190
  • VBC-GENOMICS Bioscience Research GmbH 193
  • Zeptosens AG 195
  • Zyomyx, Inc. 198
• Functional Proteomics 202
  • ActivX Biosciences, Inc. 203
  • Affinium Pharmaceuticals, Inc. 205
  • Aurelium BioPharma Inc. 208
  • AxCell Biosciences 210
  • Caprion Pharmaceuticals Inc. 212
  • Cellular Genomics Inc. 215
  • Cellzome AG 218
  • CuraGen Corporation 220
  • Cytos Biotechnology AG 222
  • ExSAR Corp. 224
  • GPC Biotech AG 226
  • Genetix Group plc 228
  • Graffinity Pharmaceuticals AG 230
  • Hybrigenics SA 232
  • Kinetek Pharmaceuticals, Inc. 235
  • MDS Proteomics, Inc. 237
  • Morphochem AG 239
  • Myriad Genetics Inc. 241
  • Odyssey Thera, Inc. 243
  • ProteEx, Inc. 245
  • ProteoSys AG 247
  • Rigel Pharmaceuticals, Inc. 249
  • Serenex, Inc. 252
  • SurroMed, Inc. 254
  • Xerion Pharmaceuticals AG 256

Chapter 6: Market Model 258

• State of the Market in 2003 259
  • Successes 259
  • Challenges 260
  • Scenarios 262
• Total Market 263
  • Companies 263
  • Size 267
• Market Model Methodology 268
  • Research and Analysis 268
  • Quantitation 269
• Market Segmentation 270
• Market Definitions 271
• Market Inclusions and Exclusions 272
• Market By Technology 273
  • Drivers 273
  • Size and Shares 274
• Market By Data Type 275
  • Drivers 275
  • Size and Shares 276
• Market By Applications 277
  • Drivers 277
  • Size and Shares 278